Previous Article | Next Article 
Molecular and Cellular Biology, September 1999, p. 6345-6354, Vol. 19, No. 9
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Direct Association and Nuclear Import of the
Hepatitis B Virus X Protein with the NF-
B Inhibitor
I
B
Robert
Weil,1
Hüseyin
Sirma,2
Carlo
Giannini,2
Dina
Kremsdorf,2
Christine
Bessia,1
Catherine
Dargemont,3
Christian
Bréchot,2 and
Alain
Israël1,*
Unité de Biologie Moléculaire de
l'Expression Génique, URA 1773 Centre National de la Recherche
Scientifique, Institut Pasteur, 75724 Paris Cedex
15,1 INSERM U370,
Carcinogénèse Hépatique et Virologie
Moléculaire, Institut Necker, 75015 Paris,2 and Laboratoire de Transport
Nucléocytoplasmique, UMR 144 Institut Curie-CNRS, 75231 Paris
Cedex 05,3 France
Received 2 February 1999/Returned for modification 25 March
1999/Accepted 27 May 1999
 |
ABSTRACT |
The X protein of hepatitis B virus (HBV) is a transcriptional
activator which is required for infection and may play an important role in HBV-associated hepatocarcinogenesis. It has been suggested that
X acts as a nuclear coactivator or stimulates several signal transduction pathways by acting in the cytoplasm. One of these pathways
leads to the nuclear translocation of NF-
B. A recent report
indicates that X activates NF-
B by acting on two cytoplasmic inhibitors of this family of transcription factors: I
B
and the precursor/inhibitor p105. We demonstrate here that X directly interacts
with I
B
, which is able to transport it to the nucleus by a
piggyback mechanism. This transport requires a region of I
B
(the
second ankyrin repeat) which has been demonstrated to be involved in
its nuclear import following NF-
B activation. Using deletion
mutants, we showed that amino acids 249 to 253 of I
B
(located in
the C-terminal part of the sixth ankyrin repeat) play a critical role
in the interaction with X. This small region overlaps one of the
domains of I
B
mediating the interaction with the p50 and p65
subunits of NF-
B and is also close to the nuclear export sequence of
I
B
, therefore providing a potential explanation for the nuclear
accumulation of I
B
with X. This association can also be observed
upon the induction of endogenous I
B
by tumor necrosis factor
alpha (TNF-
) treatment of Chang cells expressing X. In accordance
with this observation, band shift analysis indicates that X induces a
sustained NF-
B activation following TNF-
treatment, probably by
preventing the reassociation of newly synthesized nuclear I
B
with
DNA-bound NF-
B complexes.
 |
INTRODUCTION |
Hepatitis B virus (HBV) belongs to
the family Hepadnaviridae, whose members replicate their
genomes by reverse transcription, and causes both acute and chronic
infections of the liver. The gene encoding the X protein is highly
conserved among all mammalian hepatitis viruses and is expressed at low
levels during acute and chronic hepatitis (5, 25, 52, 68).
The function of X in the viral life cycle is still enigmatic. Previous
studies showed that in cell cultures transfected with viral DNA, viral replication does not depend on a functional X protein. However, X is
required for infectivity in vivo (8, 71) and thus may play
an essential role during early steps of viral infection. In addition,
several lines of evidence have implicated X in the regulation of liver
cell proliferation and viability during liver carcinogenesis (10,
16, 22, 30, 38, 52, 55). X shows transcriptional activity, but
the relevance of this property in the viral life cycle is still unclear
(32, 43, 68). X has been shown to activate a wide variety of
cellular and viral genes in trans, including HBV enhancers;
human immunodeficiency virus long terminal repeats; class II and III
promoters; the proto-oncogenes c-jun, c-fos, and
c-myc; and, recently, cytokines such as tumor necrosis
factor alpha (TNF-
) (33). The mechanism(s) by which X
activates gene transcription in trans is only partially
understood. The findings that X by itself does not bind to
double-stranded DNA and that genes stimulated by X lack any obvious
consensus sequences suggest that X stimulates transcription presumably
by interacting with cellular proteins and/or components of signal transduction pathways (14, 23). The transactivation function of X has been shown to involve both direct interaction with
transcriptional factors, such as RPB5 and RMP of RNA polymerases
(14), TATA-binding protein (40, 61), and ATF/CREB
(65), and activation of signal transduction pathways, such
as Ras/Raf/MAP kinase (4), protein kinase C (29),
Jak1-STAT signaling (34), and NF-
B (9, 35, 47, 51,
58). Although X seems to act in the nucleus to activate
transcription from certain promoters, the great majority of X is
cytosolic and is likely to act from this compartment to activate
pathways leading to the activation of promoters bearing AP-1, NF-AT, or
NF-
B sites (9, 32, 48, 51, 52). We focus here on the
mechanisms involved in X-induced NF-
B activation.
Members of the Rel/NF-
B family of transcription factors play
important roles in immune, inflammatory, and apoptotic responses, through the induction of the expression of numerous cellular and viral
genes (3, 36, 60). NF-
B activity is composed of homo- or
heterodimers of related proteins that share a conserved DNA-binding and
dimerization domain called the Rel homology domain. In most cell types,
NF-
B is sequestered in the cytoplasm bound to inhibitory proteins
called I
B
, I
B
, and I
B
. In response to diverse
stimuli, including inflammatory cytokines and mitogens, as well as
several viral proteins, active NF-
B is translocated to the nucleus
as a result of the proteolytic degradation of I
B proteins. This
mechanism has been best studied for the I
B
inhibitor and
demonstrated to involve phosphorylation on two specific serine residues
followed by ubiquitination and degradation by the 26S proteasome
(6, 7, 42, 56, 64). More recently, a specific protein kinase
activity responsible for the phosphorylation of I
B
has been
identified as a large multisubunit complex, and two kinase subunits
(IKK1/
and IKK2/
) as well as a structural component (NEMO or
IKK
) have been cloned (12, 37, 41, 44, 66, 67, 70). While
the process leading to the degradation of the I
B proteins is
relatively well understood, the mechanism by which a variety of
distinct signals are transduced to their common targets, the I
B
proteins, remains to be elucidated. This is particularly true for the
viral proteins which are known to activate NF-
B, including human
T-cell leukemia virus 1 Tax, Epstein-Barr virus LMP1, and HBV X. LMP1
has been shown to act like a constitutive TNF-like receptor
(15). Concerning Tax, the situation is less clear, despite a
number of studies suggesting that this molecule might interact with
several members of the NF-
B or I
B family. More recently, it has
been shown that Tax can interact directly with the IKK complex or with
one of the putative upstream kinases (11, 21, 59, 69). In
contrast, NF-
B activation by X has been much less studied: two
recent reports indicate that the transient expression of X induces the
degradation of two NF-
B cytoplasmic inhibitors, I
B
and the
p105 precursor of the p50 NF-
B subunit (9, 51). While the
role of the IKK complex in X-induced NF-
B activation will be the
subject of a separate study (61a), we demonstrate here that
X interacts with I
B
and I
B
but not I
B
and that the
interaction between X and I
B
results in the nuclear
colocalization of these two molecules.
We also show that I
B
is responsible for transporting X to the
nucleus; we have mapped the residues necessary for the interaction between these two proteins to amino acids 249 to 253 of I
B
. This
region overlaps the recently identified contact points between I
B
and the p50 and p65 subunits of NF-
B and is also close to the
nuclear export sequence (NES) of I
B
, therefore providing a
potential explanation for the nuclear accumulation of I
B
that is
associated with X. The observation that transfected X also associates
with newly synthesized endogenous I
B
following TNF treatment (but
not with endogenous I
B
in nonstimulated cells) suggests that
under these conditions, X could induce a sustained NF-
B activation
by preventing the reassociation of newly synthesized nuclear I
B
with DNA-bound NF-
B complexes. Indeed, band shift analysis indicated
that X induced a sustained NF-
B activation following TNF-
treatment.
 |
MATERIALS AND METHODS |
Cell culture and reagents.
Chang cells and 293T cells were
maintained in Dulbecco's modified Eagle's medium supplemented with
10% fetal calf serum, penicillin, and streptomycin (Life Technologies
Inc., Cergy Pontoise, France).
Antisera.
The antisera used were as follows. Anti-X (kindly
provided by S. Urban) is a polyclonal rabbit antiserum raised against a fusion protein between X and glutathione S-transferase
(GST). I
B
polyclonal antiserum 52008 was raised against
recombinant human I
B
(62). Anti-I
B
serum 37015 is a polyclonal rabbit antiserum generated against a GST fusion protein
encompassing amino acids 258 to 360 of mouse I
B
(62).
Anti-I
B
serum M121 was purchased from Santa Cruz. Anti-green
fluorescence protein (GFP) monoclonal antibody is from Clontech.
Anti-hemagglutinin is murine monoclonal antibody 12CA5.
Plasmids and constructs.
The expression vectors for
transfection into Chang cells were obtained by subcloning cDNAs
encoding I
B
or its derivative into the plasmid pRc-CMV or pcDNA-3
(Invitrogen). To identify the domains of I
B
required for in vivo
interaction with X protein, modified forms of I
B
(
C290,

C278, 
C260, 
C253, and 
C249) were generated by
site-directed mutagenesis with a PCR-based strategy (reference
64 and unpublished data). The deletion of amino
acids 268 to 317 of I
B
was obtained by digestion with
PvuII, and the resulting construct is referred to as

C268. Deletions were confirmed by sequencing. The X-GFP, X-myc,
and pcDNA3-X expression vectors have been described (48).
I
B
-110A3 was a kind gift from M. Hannink (46).
(His)6-I
B
was obtained by cloning a PCR-amplified I
B
cDNA
into the pRSETA vector (Invitrogen). Recombinant (His)6-I
B
was
purified according to the manufacturer's instructions. DNA encoding
the SV5-tagged version of I
B
sequences for amino acids 68 to 317 was amplified by PCR with the pcDNA-3-I
B
ctag vector (1) as a template and cloned into the
BamHI/XbaI restriction sites of eukaryotic
expression vector pEGFP-C1 (Clontech), generating pEGFP-I
B
(68-317) ctag.
Generation and purification of bacterial fusion proteins.
DNA constructs allowing the synthesis of GST fusion proteins
encompassing human I
B
or X were created by PCR and standard recombinant technology. All PCR-generated fragments were cloned into
the pGEX-2T vector (Pharmacia). They were fully sequenced to ensure
that they contained no mutation. For the production of fusion proteins,
bacterial cultures were grown to mid-log phase and then stimulated with
1 mM isopropyl-
-D-thiogalactopyranoside (IPTG). After
4 h of additional growth, the bacteria were harvested in a
solution containing 50 mM Tris-HCl (pH 8.0), 1% Nonidet P-40 (NP-40),
150 mM NaCl, 2 mM EDTA (pH 8.0), 10% glycerol supplemented with
protease inhibitors (10 µg each of leupeptin, aprotinin, N-tosyl-L-phenylalanine chloromethyl ketone
[TPCK], N
-p-tosyl-L-lysine chloromethyl ketone [TLCK], and phenylmethylsulfonyl fluoride per
ml), and phosphatase inhibitors (100 mM sodium fluoride and 2 mM sodium
orthovanadate). Fusion proteins were immobilized on glutathione coupled
to agarose beads (Sigma).
In vitro translation of pcDNA-3-X was performed with wheat germ
extracts according to the manufacturer's instructions (Promega).
Cell transfection.
Transfection of Chang cells was carried
out by the calcium phosphate coprecipitation technique. A total of 10 µg of DNA per 10-cm plate was used.
Preparation of nuclear extracts and electrophoretic mobility
shift assay.
Transfected 293T cells were pelleted and solubilized
for 5 min at 4°C in EMSA I buffer (50 mM Tris-HCl [pH 7.9], 10 mM
KCl, 1 mM EDTA, 0.2% NP-40, 10% glycerol) supplemented with protease inhibitors (10 µg each of leupeptin, aprotinin, TPCK, TLCK, and phenylmethylsulfonyl fluoride per ml) and phosphatase inhibitors (100 mM sodium fluoride and 2 mM sodium orthovanadate). The lysates were
centrifuged at 6,500 × g for 3 min. The pelleted
nuclei were washed extensively with the same buffer without NP-40 and
then incubated for 20 min at 4°C with EMSA II buffer containing 400 mM NaCl, 20% glycerol, 20 mM HEPES (pH 7.9), 10 mM KCl, 1 mM EDTA, and
protease and phosphatase inhibitors. The extracts were centrifuged at
14,000 × g for 10 min, and supernatants were used for
the mobility shift assay. The following partially double-stranded
oligonucleotide probe, KBF1, was used for the mobility shift assays:
Mobility shift assays were performed in a total volume of 20 µl in the following buffer: 4% Ficoll, 20 mM HEPES (pH 7.5), 70 mM
NaCl, 2 mM dithiothreitol, 100 µg of bovine serum albumin per ml, and
0.01% NP-40. Each reaction [mixtures also contained 1 µl of the
probe, end labelled with 32P, and 1 µg of poly(dI-dC)
(Pharmacia)] was initiated by the addition of 10 µg of nuclear
extract, and mixtures were allowed to incubate at room temperature for
20 min prior to electrophoretic analysis on a 5% native polyacrylamide
gel in 0.5× Tris-borate-EDTA buffer.
Immunoprecipitations and immunoblots.
Cells were lysed by
adding 250 µl of 1× Chris buffer (50 mM Tris [pH 8.0], 0.5%
NP-40, 200 mM NaCl, and 0.1 mM EDTA) as well as the protease and
phosphatase inhibitors described above to 5 × 105
cells. Specific polypeptides were then recovered by immunoprecipitation from equivalent amounts of cellular proteins, using one of the following antibodies: anti-I
B
, anti-I
B
, anti-I
B
,
anti-X, or anti-GFP. Immune complexes were collected with
Staphylococcus aureus protein A (Pansorbin; Calbiochem) or
protein G-Sepharose (Sigma). Immunoprecipitates were then washed three
times in lysis buffer and resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Subsequent immunoblot
analyses were performed according to a previously described protocol.
Anti-GFP monoclonal antibody was used at a 1/500 dilution.
Anti-I
B
, anti-I
B
, anti-I
B
, and anti-X were used at a
1/1,000 dilution for enhanced chemiluminescence (ECL) or 1/200 for
125I-protein A, as indicated in the figure legends.
Proteins transferred to Immobilon membranes (Millipore) were revealed
either with the Amersham ECL system (for immunoblotting of mouse
monoclonal immunoprecipitates or for direct immunoblotting of total
cell extracts) or by incubation with 125I-protein A
(Amersham) (for immunoblotting of rabbit polyclonal immunoprecipitates).
In vitro binding assays.
In vitro-translated X or
recombinant (His)6-I
B
was added to immobilized GST fusion
proteins in 1× Chris buffer. To avoid the formation of mixed disulfide
bonds, the buffer was supplemented with 0.5 mM dithiothreitol. The
mixtures were incubated at 4°C for an hour with gentle rotation. The
agarose beads were washed three times with 1 ml of 1× Chris buffer.
Bound proteins were subsequently eluted with sample buffer, boiled, and
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Indirect immunofluorescence.
Our procedure has been
described previously (48). Briefly, Chang cells were seeded
onto coverslips and transfected. After 30 to 40 h, the cells were
either fixed in 3% paraformaldehyde, rinsed, and permeabilized in
phosphate-buffered saline containing 0.2% Triton or fixed and
permeabilized with methanol and acetone, blocked with goat serum, and
incubated with primary antibody at a 1/100 dilution for 1 h at
room temperature. The secondary antibody was anti-rabbit immunoglobulin
G conjugated with Texas red (Vector Laboratory) or fluorescein
isothiocyanate (Sanofi Diagnostics Pasteur) at a 1:60 dilution. We used
also Texas red-conjugated anti-mouse immunoglobulin G at the same
dilution (Sigma). After being washed in phosphate-buffered saline,
coverslips were mounted in Mowiol, and cells were examined with an
epifluorescence microscope (Zeiss). Alternatively, confocal laser
scanning microscopy and immunofluorescence analysis were performed with
a TCS4D confocal microscope based on an immunofluorescence microscope
interfaced with a mixed-gas (argon-krypton) laser (Leica Laser
Technic). Fluorescence acquisition was performed with the 488- and
568-nm lasers to excite the fluorescein isothiocyanate and Texas red dyes, respectively, with a 100× oil immersion PL APO objective.
 |
RESULTS |
Interaction between X and I
B
.
Expression of the HBV X
protein results in NF-
B activation by an incompletely characterized
mechanism, possibly involving phosphorylation of the I
B
molecules
by the recently characterized IKK complex. As Tax, another viral
protein known to activate NF-
B, has been suggested to directly
interact with members of the NF-
B and I
B families, the
possibility that X could directly interact with I
B molecules in vivo
and in vitro was evaluated.
To assay for a possible interaction between X and I
B
, we
cotransfected X-GFP and I
B
expression vectors in Chang cells and
carried out coimmunoprecipitations. As depicted in Fig.
1A, precipitation of I
B
followed by
immunoblotting for X demonstrated the association between these
proteins (lanes 12 and 15). Anti-GFP blotting detected X-GFP only in
the presence of I
B
, but not when X-GFP, I
B
, or I
B
was
expressed alone (Fig. 1A, top, lanes 9 through 11) or when X-GFP was
coexpressed with I
B
(lane 13). No association could be seen when
normal rabbit serum (NRS) was used for immunoprecipitation (lane 1). We
also confirmed that the interaction of X-GFP with I
B
was not
mediated by GFP (lane 14). In the bottom panel of Fig. 1A, an
anti-I
B
immunoblot of I
B
immunoprecipitates verified in
parallel the level of endogenous and exogenous I
B
. The reverse
experiment (the immunoprecipitation of X-GFP with anti-GFP followed by
immunoblotting with anti-I
B
) confirmed the interaction between
X-GFP and I
B
(Fig. 1B, lane 5). Importantly, a direct I
B
immunoblot of the corresponding cellular lysates (lanes 6 through 9)
indicated that the augmented presence of I
B
in the anti-GFP
immunoprecipitate (lane 5) was not due to a change in its cellular
abundance.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 1.
X associates with I B but not with I B or
I B . (A) Chang cells were transfected with the indicated cDNAs
( , I B ; , I B ). After 30 h, lysates were
immunoprecipitated (IP) with NRS, anti-X, or anti-I B .
Immunoblotting was performed with anti-GFP monoclonal antibody followed
by ECL (top) or anti-I B polyclonal antibody followed by
incubation with 125I-protein A (bottom). (B) After
transfection with the indicated plasmids, I B was detected by
immunoblotting of total cell lysates (lanes 6 to 9) or
anti-hemagglutinin (HA) (as a nonrelevant control antibody [lane 1])
or anti-GFP (to detect X-GFP [lanes 2 to 5]) immunoprecipitates. (C)
(Left) Binding of 35S-labelled in vitro-translated X to a
GST-I B column. A total of 0 (lane 1), 1 (lane 2), 5 (lane 3), or
10 (lane 4) µl of the translated product was incubated with the
bacterially produced GST fusion protein. After extensive washing, bound
35S-X was detected by autoradiography. One microliter of
the wheat germ extract translation product was run in parallel (lane
5). (Right) Binding of (His)6-I B (His- ) to GST-X. One
microliter (50 ng) of (His)6-I B was incubated with GST-X (lane 1)
or GST (lane 2). After extensive washing, the level of I B was
determined by immunoblotting. To quantify the interaction, we loaded
1.5 ng of (His)6-I B on the gel (lane 3). (D) Chang cells were
transfected with the indicated cDNAs. Lysates were immunoprecipitated
(IP) with NRS or immunopurified anti-I B and immunoblotted with
anti-GFP or anti-I B . (E) Same as panel D, but with I B . Cell
extracts were immunoprecipitated with NRS (lane 1) or immunopurified
anti-I B (lanes 2 to 7) before immunoblotting with anti-GFP (top).
To evaluate the expression of X-GFP in total lysates, we performed an
immunoblot with an anti-GFP antibody.
|
|
The specificity of this interaction was then examined in vitro with GST
pull-down experiments: GST fusion proteins encompassing I
B
or X
were produced in bacteria, immobilized on agarose-glutathione beads,
and used to detect, respectively, their association with in
vitro-translated 35S-labelled X (Fig. 1C, left) or
(His)6-I
B
(right). The addition of increasing amounts of
35S-labelled X protein resulted in a parallel augmentation
of its interaction with GST-I
B
fusion protein (Fig. 1C, left,
lanes 2 and 3), with a plateau for the highest concentration (left, lane 4). Recombinant (His)6-I
B
was incubated with equivalent amounts of immobilized GST or GST-X (Fig. 1C, right) and found to be
associated only with GST-X, demonstrating specific association between
I
B
and X (right, lane 1).
The finding that I
B
associates with X raised the possibility that
the two other NF-
B inhibitors, I
B
and I
B
, could also interact with X. To examine this possibility, Chang cells were transfected with plasmids encoding these proteins and/or X-GFP. Lysates
were subjected to immunoprecipitation with NRS as a negative control,
immunopurified anti-I
B
antiserum (Fig. 1D), or anti-I
B
antiserum (Fig. 1E), and the presence of X-GFP was determined by
anti-GFP immunoblotting. These experiments did not demonstrate any
significant interaction between X and I
B
(Fig. 1D, lane 7);
however, when the cells were transfected with X or cotransfected with X
and I
B
, we observed an association of X with either endogenous (lane 3) or transfected (lane 7) I
B
. The abundance of I
B
was also measured by anti-I
B
immunoblotting (Fig. 1D, bottom) to ensure that it was efficiently expressed and immunoprecipitated. As the
bottom part of Fig. 1E shows, a direct GFP immunoblot of the
corresponding cellular lysates (lanes 6 through 9) indicated that the
augmented presence of X-GFP in the anti-I
B
immunoprecipitate (lane 7) was not due to a change in its cellular abundance.
In conclusion, these data demonstrate that X and I
B
interact both
in vitro and ex vivo. Moreover, this interaction also occurs with
I
B
but not with I
B
.
I
B
promotes the import and accumulation of X in the
nucleus.
To evaluate whether the association between X and
I
B
induces a change in subcellular distribution of these
proteins, overexpressed X and I
B
were localized by indirect
immunofluorescence. I
B
, detected with an immunopurified
anti-I
B
antibody, was localized to the cytoplasm and the nucleus
in Chang cells with a diffuse distribution (Fig.
2A). To study the subcellular
localization of X, we took advantage of the fusion construct between X
and the reporter GFP. As was previously reported, X-GFP showed a
discrete granular appearance and was distributed throughout the
cytoplasm (Fig. 2B and reference 48). In contrast,
when cotransfected with I
B
, X exhibited a nuclear distribution in
large structures (Fig. 2D), and double staining indicated that X and
I
B
colocalized in these nuclear structures (Fig. 2E). To ensure
that fusion with GFP did not alter the nuclear localization of X, we
performed immunofluorescence analysis in cells cotransfected with a
plasmid carrying a gene encoding a myc-tagged form of X
(X-myc) and pEGFP-I
B
(68-317) ctag cDNA. As shown in Fig. 2G,
X-myc (in red) exhibited a nuclear distribution that overlaps with
nuclear structures observed with GFP-I
B
(68-317) (Fig. 2F). Double
staining indicated that X and GFP-I
B
(68-317) colocalized in these
nuclear structures (Fig. 2H). Thus, the presence of I
B
induced a
relocalization of the majority of X to the nucleus. In agreement with
our biochemical results (Fig. 1D), we could not detect any effect of
I
B
on the subcellular localization of X (data not shown).

View larger version (77K):
[in this window]
[in a new window]
|
FIG. 2.
Colocalization of X and I B in the nucleus. Chang
cells were transfected with plasmids expressing I B and/or X-GFP
and fixed 30 h after transfection. The cellular distribution of X
was visualized by the reporter GFP, and I B was visualized by
immunostaining with purified anti-I B antibody followed by Texas
red-conjugated anti-rabbit antibody. (A) Cells transfected with
I B alone and stained with anti-I B . (B) Cells transfected
with X-GFP alone and subjected to immunofluorescent detection of GFP.
(C to E) Cells cotransfected with I B and X-GFP and stained for
I B (C), GFP (D), or both (E); areas of coincidence of red and
green fluorescence (yellow) indicate overlapping distributions of X and
I B . Panel E shows fluorescence superimposed on a Nomarski image.
(F to H) Cells cotransfected with pEGFP-I B (68-317) and X-myc were
stained for GFP and X-myc. The localization of GFP-I B (68-317) is
visualized by its green fluorescence (F), whereas X-myc is detected in
red (G). Panel H shows fluorescence superimposed on a Nomarski image.
|
|
To get insight into the mechanism responsible for X nuclear
localization, X was coexpressed in Chang cells with I
B
-110A3. This variant of I
B
is mutated in the second ankyrin repeat, a
region responsible for the nuclear import of I
B
, and therefore remains predominantly cytoplasmic when ectopically expressed (46, 57). The subcellular distribution of I
B
-110A3 and X was
determined by indirect immunofluorescence. X was found exclusively in
the cytoplasm. As previously reported, I
B
-110A3 displayed a
diffuse cytoplasmic localization (Fig.
3A) and was also found in cytoplasmic dots containing X (Fig. 3B and C). Coimmunoprecipitation experiments confirmed that X interacts with I
B
-110A3 (data not shown).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
Colocalization of X and mutant I B -110A3 in the
cytoplasm. Chang cells were cotransfected with plasmids expressing
I B -110A3 and X-GFP and fixed 30 h after transfection.
I B -110A3 was visualized by immunostaining with purified
anti-I B antibody followed by Texas red-conjugated anti-rabbit
antibody (A). The subcellular distribution of X was visualized by the
reporter GFP (B). The distribution of both fluorochromes, superimposed
on a Nomarski image, is shown in panel C. Areas of coincidence of red
and green fluorescence (yellow) indicate overlapping distributions of X
and I B -110A3.
|
|
These data indicate that a mutation which impairs the ability of
I
B
to translocate to the nucleus is sufficient to prevent the
nuclear accumulation of X. Together, these data show that I
B
is
able to transport X to the nucleus by a piggyback mechanism.
Mapping of the domain for interaction of I
B
with X.
To
analyze the site of binding of I
B
to X, we employed both
wild-type I
B
(
wt) and a series of C-terminal-deletion mutants of I
B
termed 
C290, 
C278, 
C268, 
C253, and

C249. All these proteins were efficiently immunoprecipitated by
the polyclonal anti-I
B
antibody (Fig.
4, bottom). When X was coexpressed in vivo with these proteins, it could associate with mutants 
C290, 
C278, 
C268 (Fig. 4, left, lanes 3 to 5), and 
C253
(Fig. 4, right, lane 3), but binding was hardly visible with mutant 
249 (Fig. 4, right, lane 4). Parallel immunoblotting with GFP confirmed that X-GFP was normally expressed in each immunoprecipitate. We confirmed these results by the immunofluorescence of cotransfected cells (Fig. 5). I
B
mutants

C260 and 
C253 colocalized with X in nuclear structures
(Fig. 5A through C and D through F, respectively), but mutant

C249 showed no colocalization with X and no evidence of punctate
structures, while X remained fully cytoplasmic (Fig. 5G through I).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Structural requirement for I B -X interaction. Chang
cells were transiently transfected with X-GFP expression vector (lanes
1) or cotransfected with X-GFP and plasmids encoding various mutants of
I B : wt,  C290,  C278,  C268,  C253, and
 249. Cell lysates were immunoprecipitated with anti-I B
antiserum and analyzed by immunoblotting with a monoclonal anti-GFP
antibody or a polyclonal anti-I B antibody.  C268 migrates
more slowly than  C278 because it contains a few extra C-terminal
amino acids derived from the cloning vector (this extra sequence does
not interfere with its activity [data not shown]).
|
|

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 5.
Structural requirement for I B -X colocalization.
Chang cells were cotransfected with X-GFP and plasmids expressing
either  C260 (A to C),  C253 (D to F), or  C249 (G to
I). Cells were analysed by immunofluorescence with immunopurified
anti-I B antibody (A, D, and G) or directly tested for GFP
fluorescence (B, E, and H) and visualized by confocal laser scanning
microscopy. Merging of the two stainings is shown in panels C, F, and
I.
|
|
X interacts with endogenous I
B
following TNF-
treatment.
Because we were not able to detect an association
between X and endogenous I
B
(Fig. 1A, lane 9), we decided to
evaluate this interaction in cells treated with TNF-
, a situation
where free I
B
is resynthesized following degradation (Fig.
6). Chang cells transfected with X-GFP
cDNA were subjected to a time course of TNF-
stimulation (Fig. 6,
lanes 1 to 7), whereas mock-transfected cells were left untreated (lane
8) or stimulated for 15 min with TNF-
(lane 9). Following these
treatments, cell lysates were subjected to immunoprecipitation with an
anti-I
B
antiserum, followed by immunoblotting with anti-GFP to
evaluate X-GFP-I
B
association (Fig. 6, top) or with
anti-I
B
to evaluate the kinetics of I
B
degradation and
resynthesis (middle). The anti-I
B
Western blot demonstrates that
I
B
was partially degraded at 15 min (this degradation seemed to
be more effective in the presence of X; compare Fig. 6, middle, lanes 2 and 9) and was progressively resynthesized from 30 min to 6 h
(lanes 3 to 6). Monitoring the interaction between X and I
B
demonstrated that such interaction occurred only when I
B
was
resynthesized (Fig. 6, top, lanes 3 to 6). Indeed, despite observing a
larger amount of I
B
visible in nontreated cells, we could not
detect any association with X-GFP (Fig. 6, top; compare lane 1 with
lanes 3 to 6). A parallel Western blotting of total cell lysates with
an anti-GFP antibody showed the level of expression of X-GFP. The
reduced expression of I
B
and X-GFP after 18 h of TNF-
treatment (Fig. 6, top and middle, lanes 7) could be a consequence of
cell apoptosis upon long treatment with TNF-
and X.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 6.
Association of X with newly synthesized I B . Chang
cells transfected with X (lanes 1 to 7) or mock transfected (lanes 8 and 9) were stimulated for the indicated periods of time with TNF- ,
lysed in 1× Chris buffer, and subjected to anti-I B
immunoprecipitation followed by anti-GFP or anti-I B
immunoblotting. The abundance of X-GFP was measured by immunoblotting
of lysates with an anti-GFP monoclonal antibody (bottom).
|
|
X sustained NF-
B activation following TNF-
treatment.
Our results demonstrate that a region of I
B
critical for
interaction with X encompasses amino acids 249 to 253. The recent resolution of the I
B
-NF-
B complexes (27, 28)
demonstrates that this region also directly contacts either p50 or p65
(see Discussion). Therefore, it is possible that X might interfere with
the reassociation of newly synthesized nuclear I
B
with DNA-bound
NF-
B complexes and thus prevent the termination of the activation process.
To test this possibility, nuclear NF-
B DNA-binding activity was
assayed in 293T cells treated or not with TNF-
in the presence or
absence of transfected X-GFP (Fig. 7).
DNA-binding activity was not detected in unstimulated 293T cells (Fig.
7, lane 1) but was strongly induced after the addition of TNF-
for
30 min (lane 2). When the cytokine was removed for an additional
120-min chase period, NF-
B activity was completely abolished (lane
3) as a consequence of I
B
resynthesis, nuclear import, and
NF-
B withdrawal. The transient expression of the X-GFP plasmid in
293T cells led to some NF-
B activation (lane 4), although it was at
a much lower level than activation following TNF-
treatment (lane
2). This activation was potentiated by treatment with TNF-
(lane 5).
Interestingly, during the chase period, X sustained NF-
B DNA-binding
activity (lane 6) to a level higher than that observed either with X
alone (lane 4) or after the chase period in the absence of X (lane 3).

View larger version (71K):
[in this window]
[in a new window]
|
FIG. 7.
X prolongs TNF- -induced NF- B activation. 293T
cells either mock transfected (lanes 1 to 3) or transfected with GFP-X
(lanes 4 to 6) for 30 h were either left untreated (lanes 1 and
4), treated for 30 min with TNF- (lanes 2 and 5), or treated with
TNF- , followed by extensive washing and a 120-min chase in culture
medium (lanes 4 and 6). Nuclear extracts were prepared, and band shift
assays were performed as indicated in Materials and Methods.
|
|
 |
DISCUSSION |
A body of evidence points to X as an important regulator of HBV
genome expression, infection, and proliferation and viability in liver
cells. This has been correlated by several studies suggesting that X
can bind cellular proteins, such as P53, DNA repair proteins, proteasome subunits, and Jak1 (17, 26, 34, 49, 54). The
actual specificity and in vivo relevance of such findings are, however,
still debated.
One example of the potential interaction between X and cellular
metabolism is the capacity of X to activate the NF-
B signaling pathway. A recent report indicates that X activates this pathway by
acting on two cytoplasmic inhibitors of the NF-
B family of transcription factors, I
B
and the precursor/inhibitor p105
(51). Our results provide an additional mechanism which in
part accounts for the activation of NF-
B by demonstrating that X
directly interacts with the I
B
inhibitor. A structure-function
analysis of I
B
has allowed definition of several functional
domains: a core domain of six ankyrin repeats; an N-terminal region
containing two serine and two lysine residues involved in
signal-induced phosphorylation and ubiquitination, respectively; and a
C-terminal PEST domain. More recently, a region responsible for the
nuclear import of I
B
has been identified in its second ankyrin
repeat (46, 57), and a leucine-rich NES (from amino acids
266 to 281) in the C-terminal part of the sixth ankyrin repeat has been
characterized (1, 19). The current understanding of the
roles of these two sequences is as follows: following signaling and
degradation of the I
B inhibitors, I
B
molecules are quickly
resynthesized and translocated to the nucleus. This translocation
requires the presence of the second ankyrin repeat. Once in the
nucleus, these newly synthesized free I
B
molecules dissociate
NF-
B complexes from DNA and transport them back to the cytoplasm
(1). This step requires the presence of the NES; this
sequence is homologous to the nuclear export signal found in human
immunodeficiency virus Rev and the inhibitor of protein kinase A and is
specifically recognized by the nuclear protein CRM1, which promotes the
export from the nucleus to the cytoplasm (18, 20, 39, 50).
Therefore, the localization of I
B
is the result of a dynamic
equilibrium between nuclear import and export, also controlled by the
accessibility of two sequences, the one in the second ankyrin repeat
and the NES.
We demonstrate here that the X protein directly interacts with a region
of the I
B
inhibitor located towards the N-terminal part of the
sixth ankyrin repeat. Interestingly, while X has been shown to be
essentially cytoplasmic, the cotransfection of X and I
B
results
in the nuclear colocalization of the two molecules. This localization
is dependent on the presence of a functional nuclear import region in
I
B
, demonstrating that it is not due to unmasking of a cryptic
NLS sequence in X. In order to characterize the nuclear localization of
X-I
B
complexes, we performed double indirect immunofluorescence
studies using antibodies specifically recognizing different punctate
structures in the nucleus, such as SC-35 (a spliceosome assembly
factor), SP-10, SM-1, and PML (31). However, the
distribution pattern of these proteins was distinctly different from
that of X (data not shown).
These results raise two questions: (i) why are the two molecules
localized to the nucleus, and (ii) what is the physiological implication of this phenomenon?
A deletion analysis demonstrated that the region encompassing amino
acids 249 to 253 of I
B
is critical for the interaction with X. A
deletion mutant of I
B
containing amino acids 1 to 249 showed no
association or colocalization with X, while a construct containing
amino acids 1 to 253 exhibited a behavior similar to that of the
wild-type molecule. The localization of this region is interesting in
view of the recent resolution of the structure of a p50-p65-I
B
complex (27, 28). The domain for interaction between
I
B
and X is located in the N-terminal region of the sixth ankyrin
repeat, while the NES is in the C-terminal part of this repeat. The
structure shows that these two regions are not far from each other, and
it is conceivable that interaction between I
B
and X might
interfere with the accessibility of the NES to the export machinery. As
the subcellular localization of I
B
is the result of an
equilibrium between import (controlled by the second ankyrin repeat)
and export (controlled by the NES), masking of the latter sequence
would provide an explanation for the nuclear colocalization and
accumulation of the two molecules. A similar situation has recently
been described (45): complexes between the v-rel
oncogene product and I
B
are localized to the cytoplasm, but the
treatment of cells with leptomycin, a specific inhibitor of
CRM1-mediated nuclear export, results in nuclear relocalization of the
v-rel-I
B
complex, indicating that continuous nuclear
export is required for the cytoplasmic retention of this complex.
Experiments are in progress to determine whether interaction between X
and I
B
prevents access to the I
B
NES and, in particular, prevents binding of CRM1 to the NES.
Another important piece of information provided by the crystal
structure concerns the contact points between I
B
and p50 or p65
(27, 28). Amino acids 249, 251, 255, 256, 258, 259, and 260 of I
B
directly contact either p50 or p65. Therefore, it is likely
that the interaction of I
B
with X would interfere with
I
B
's interaction with NF-
B. One possibility is that X might
be able to dissociate preformed NF-
B-I
B
complexes and therefore induce a sustained nuclear localization of NF-
B complexes. However, we have been unable to demonstrate dissociation of
NF-
B-I
B
complexes by recombinant X (data not shown); this is
in agreement with the observation that X is unable to interact with
endogenous I
B
in nonstimulated cells (Fig. 6). Another
possibility is that X associates and translocates to the nucleus with
newly synthesized free I
B
. Free I
B
has been observed in
cells treated with a NF-
B-activating stimulus, such as TNF-
:
following stimulation, newly synthesized I
B
translocates to the
nucleus, where it dissociates NF-
B complexes from DNA and takes them
back to the cytoplasm. Figure 6 indicates that newly synthesized
endogenous I
B
indeed associates with X. Therefore, this
association might prevent I
B
from interacting with DNA-bound
NF-
B complexes and lead to sustained NF-
B activation. This
hypothesis was strengthened by the observation that in the presence of
X, the complete disappearance of nuclear NF-
B DNA-binding activity
which had been observed after TNF-
treatment following a chase
period (2) could no longer be observed, and sustained
NF-
B activity was detected (Fig. 7).
X interacts with a region of I
B
which is well conserved among
other I
Bs; however, interaction could be observed with I
B
but
not with I
B
. The significance of the association with I
B
is
currently unknown. I
B
has not been demonstrated to shuttle between the cytoplasm and nucleus, and the association between X and
endogenous I
B
in nonstimulated cells (contrary to what is
observed with I
B
) suggests that this might fulfill a different function. Further experiments are required to clarify this point.
I
B
is not the only inhibitor which has been demonstrated to be
present in the nucleus: an underphosphorylated form of I
B
has
indeed been demonstrated to translocate to the nucleus in association
with NF-
B complexes, but it has been postulated to induce a
prolonged NF-
B activation. The specific association of X with
I
B
and the postulated mechanism described above are consistent
with the observation that I
B
is the only I
B known to date to
exhibit an inhibitory function in the nucleus.
The subcellular localization of X is still debated. Most studies have
suggested a mainly cytoplasmic localization (13, 48, 53),
and members of our groups have, in particular, demonstrated the
colocalization of X with proteasome in this compartment
(48). Some studies have suggested, however, that X might
also show a nuclear localization with the nuclear and cytoplasmic X
modulating the cellular signal transduction networks differently
(13). Thus, nuclear X might directly interact with the
transcription machinery and act as a coactivator (14, 24).
Our data should help to reconcile such apparently contradictory
findings. We indeed demonstrate that TNF-
stimulation leads to the
nuclear localization of X through its binding to I
B
. Inflammation
is a hallmark of chronic hepatitis and is associated with cytokine
synthesis. Collectively, the results suggest a model whereby X, despite
its major cytoplasmic localization, might transiently interact with the
nuclear machinery.
While it is likely that this unusual interaction per se cannot be
solely responsible for NF-
B activation (61a), especially in view of the fact that X is unable by itself to dissociate preformed NF-
B-I
B
complexes, it is likely to play a role in the
establishment of a prolonged NF-
B response. We are currently
addressing this question by trying to isolate mutants of I
B
that
no longer interact with X but keep their NF-
B inhibitory functions;
by reintroducing these molecules into I
B
/
fibroblasts and
determining the parameters of X-induced NF-
B activation on both
wild-type and mutant I
B
backgrounds, we will be able to assign a
role to this interaction.
 |
ACKNOWLEDGMENTS |
R.W. and H.S. contributed equally to this work.
We thank S. Whiteside for the gift of the C-terminal-deletion mutants
of I
B
. We are grateful to R. Hellio for technical assistance with
confocal microscopy. We thank S. Urban for the gift of anti-X antibody.
We thank M. Hannink for the gift of the I
B
-110A3 mutant.
This research was sponsored in part by grants from ARC, ANRS, and the
Ligue Nationale contre le Cancer and by Biomed contract 97-2567 and TMR
contract 960026 to A.I.; grants from INSERM, EU, ARC, the Ligue
Nationale contre le Cancer, and CNAM to C.B.; and grants from ARC and
the Ligue Nationale contre le Cancer to C.D. R.W. is a recipient
of a long-term fellowship from SIDACTION. H.S. is a recipient of a
fellowship from DFG. C.G. is a recipient of a fellowship from FRM.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Unité de
Biologie Moléculaire de l'Expression Génique, URA 1773 CNRS, Institut Pasteur, 25 Rue du Dr. Roux, 75724 Paris Cedex 15, France. Phone: 33 1 45 68 85 53. Fax: 33 1 40 61 30 40. E-mail:
aisrael{at}pasteur.fr.
 |
REFERENCES |